As pain management evolves, R.Ph.s can play a greater role

The pain management pharmaceuticals market in the U.S. is being driven by the continued development of selective cyclooxygenase-2 (COX-2) inhibitors, triptans, and extended-release formulations of opioid drugs, according to new analysis by the consulting firm of Frost & Sullivan. In 1997, the company released a similar report. In the intervening six years, the market has undergone dramatic changes.